The kids lost: GLP-1 agonists will have NAOIN in their instructions.
The FDA has ordered a single warning for each class of GLP-1 agonists (Ozempi, Vegas, Mongero, Zepbound and at least 8 other drugs) about the risk of a rare eye disease, nonarterial ischemic anterior optic neuropathy (NAOIN), which leads to vision loss. A meta-analysis of 126 trials (78,217 patients) showed 6.4 cases per 100,000 patient-years for GLP-1 versus 3.8 for controls; The indications are not limited.
Risk of going blind X2. Thin and blind - coming soon to Channel Six! Because of this side effect they don't buy ads from me about events around these drugs.
remark. While the industry is cutting coupons ($36+ billion for Lilly and $36+ billion for Novo in 2025 alone), the FDA has quietly added a warning about the possibility of going blind in one eye - and Wall Street analysts are already reassuring investors that "the risk is absolutely low, nothing threatens the business."
Why is this important? For millions of GLP-1 patients, it's a reason to discuss existing vision risk factors with a doctor; For the market - the first brand with a real risk against the background of the rampant hype around weight loss injections.
which I talked about last year.